MiNK Therapeutics opens randomized phase 2 Agent 797 study
MiNK Therapeutics says it moved Agent 797 into a randomized phase 2 study for acute lung injury and ARDS and reported narrowed net loss of $3.1 million with cash and equivalents of $8.8 million.